ARGX vs. COR: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ARGX and COR, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
ARGX trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, COR is a standard domestic listing.
| Symbol | ARGX | COR |
|---|---|---|
| Company Name | argenx SE | Cencora, Inc. |
| Country | Netherlands | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Providers & Services |
| Market Capitalization | 57.26 billion USD | 70.68 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | May 18, 2017 | April 4, 1995 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of ARGX and COR by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | ARGX | COR |
|---|---|---|
| 5-Day Price Return | 4.64% | -0.74% |
| 13-Week Price Return | 36.00% | 23.60% |
| 26-Week Price Return | 53.81% | 29.73% |
| 52-Week Price Return | 40.86% | 44.79% |
| Month-to-Date Return | 10.52% | 7.14% |
| Year-to-Date Return | 29.97% | 61.09% |
| 10-Day Avg. Volume | 0.07M | 1.79M |
| 3-Month Avg. Volume | 0.10M | 1.39M |
| 3-Month Volatility | 27.99% | 22.77% |
| Beta | 1.00 | 0.65 |
Profitability
Return on Equity (TTM)
ARGX
17.59%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
In the upper quartile for the Biotechnology industry, ARGX’s Return on Equity of 17.59% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
COR
125.17%
Health Care Providers & Services Industry
- Max
- 24.67%
- Q3
- 15.54%
- Median
- 8.37%
- Q1
- 5.49%
- Min
- -2.09%
COR’s Return on Equity of 125.17% is exceptionally high, placing it well beyond the typical range for the Health Care Providers & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
ARGX
-23.60%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
ARGX has a negative Net Profit Margin of -23.60%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
COR
0.48%
Health Care Providers & Services Industry
- Max
- 9.33%
- Q3
- 4.80%
- Median
- 2.90%
- Q1
- 0.93%
- Min
- -3.28%
Falling into the lower quartile for the Health Care Providers & Services industry, COR’s Net Profit Margin of 0.48% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.
Operating Profit Margin (TTM)
ARGX
-40.34%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
ARGX has a negative Operating Profit Margin of -40.34%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
COR
0.81%
Health Care Providers & Services Industry
- Max
- 18.35%
- Q3
- 8.71%
- Median
- 5.10%
- Q1
- 2.10%
- Min
- -3.07%
COR’s Operating Profit Margin of 0.81% is in the lower quartile for the Health Care Providers & Services industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
Profitability at a Glance
| Symbol | ARGX | COR |
|---|---|---|
| Return on Equity (TTM) | 17.59% | 125.17% |
| Return on Assets (TTM) | 15.24% | 2.14% |
| Net Profit Margin (TTM) | -23.60% | 0.48% |
| Operating Profit Margin (TTM) | -40.34% | 0.81% |
| Gross Profit Margin (TTM) | 90.83% | 3.51% |
Financial Strength
Current Ratio (MRQ)
ARGX
5.60
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
ARGX’s Current Ratio of 5.60 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
COR
0.90
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.56
- Median
- 1.28
- Q1
- 0.92
- Min
- 0.01
COR’s Current Ratio of 0.90 falls into the lower quartile for the Health Care Providers & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
ARGX
0.01
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
ARGX’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
COR
4.38
Health Care Providers & Services Industry
- Max
- 2.41
- Q3
- 1.39
- Median
- 0.74
- Q1
- 0.46
- Min
- 0.00
With a Debt-to-Equity Ratio of 4.38, COR operates with exceptionally high leverage compared to the Health Care Providers & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio (TTM)
ARGX
-81.88
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
ARGX has a negative Interest Coverage Ratio of -81.88. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
COR
8.75
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.46
- Median
- 4.52
- Q1
- 2.04
- Min
- -4.44
COR’s Interest Coverage Ratio of 8.75 is in the upper quartile for the Health Care Providers & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | ARGX | COR |
|---|---|---|
| Current Ratio (MRQ) | 5.60 | 0.90 |
| Quick Ratio (MRQ) | 4.92 | 0.54 |
| Debt-to-Equity Ratio (MRQ) | 0.01 | 4.38 |
| Interest Coverage Ratio (TTM) | -81.88 | 8.75 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
ARGX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ARGX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
COR
0.62%
Health Care Providers & Services Industry
- Max
- 5.51%
- Q3
- 2.66%
- Median
- 1.06%
- Q1
- 0.00%
- Min
- 0.00%
COR’s Dividend Yield of 0.62% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
ARGX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ARGX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
COR
22.69%
Health Care Providers & Services Industry
- Max
- 187.56%
- Q3
- 81.14%
- Median
- 33.42%
- Q1
- 0.00%
- Min
- 0.00%
COR’s Dividend Payout Ratio of 22.69% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | ARGX | COR |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.62% |
| Dividend Payout Ratio (TTM) | 0.00% | 22.69% |
Valuation
Price-to-Earnings Ratio (TTM)
ARGX
36.34
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
ARGX’s P/E Ratio of 36.34 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
COR
45.34
Health Care Providers & Services Industry
- Max
- 48.86
- Q3
- 32.22
- Median
- 21.78
- Q1
- 13.97
- Min
- 8.01
A P/E Ratio of 45.34 places COR in the upper quartile for the Health Care Providers & Services industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
Price-to-Sales Ratio (TTM)
ARGX
29.31
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
ARGX’s P/S Ratio of 29.31 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
COR
0.22
Health Care Providers & Services Industry
- Max
- 3.66
- Q3
- 1.64
- Median
- 0.72
- Q1
- 0.27
- Min
- 0.10
In the lower quartile for the Health Care Providers & Services industry, COR’s P/S Ratio of 0.22 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
ARGX
5.46
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
ARGX’s P/B Ratio of 5.46 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
COR
34.68
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.33
- Median
- 2.48
- Q1
- 1.31
- Min
- 0.65
At 34.68, COR’s P/B Ratio is at an extreme premium to the Health Care Providers & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | ARGX | COR |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 36.34 | 45.34 |
| Price-to-Sales Ratio (TTM) | 29.31 | 0.22 |
| Price-to-Book Ratio (MRQ) | 5.46 | 34.68 |
| Price-to-Free Cash Flow Ratio (TTM) | -- | 11.54 |